Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sprint Bioscience ABOSTO:SPRINT 27 Net Cash per Share is kr0.75 as of Jun. 2026. GuruFocus rates OSTO:SPRINT with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 774 Biotechnology companies, Sprint Bioscience AB ranks better than 58.79% on this metric.
The historical rank and industry rank for Sprint Bioscience AB's Net Cash per Share or its related term are showing as below:
OSTO:SPRINT'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.41 Med: 6.86 Max: 895.06
Current: 3.93
During the past 12 years, the highest Price-to-Net-Cash Ratio of Sprint Bioscience AB was 895.06. The lowest was 1.41. And the median was 6.86.
OSTO:SPRINT's Price-to-Net-Cash is ranked better than 58.79% of 774
companies
in the Biotechnology industry
Industry Median: 4.915
vs OSTO:SPRINT: 3.93
Sprint Bioscience AB (OSTO:SPRINT) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Sprint Bioscience AB Net Cash per Share Related Terms
Sprint Bioscience AB Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Sprint Bioscience AB's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SPRINT vs VRTX, REGN, MRNA: Net Cash per Share Comparison
For the Biotechnology subindustry, Sprint Bioscience AB's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sprint Bioscience AB Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Sprint Bioscience AB's Price-to-Net-Cash falls into.
Sprint Bioscience AB Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Sprint Bioscience AB's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sprint Bioscience AB (OSTO:SPRINT) has a Net Cash per Share of kr0.75 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Sprint Bioscience AB and its competitors. According to the industry distribution chart, Sprint Bioscience AB ranks #319 out of 774 companies in the Biotechnology industry, placing it in the top 41.2%.
Is Sprint Bioscience AB's Net Cash per Share too high?
Sprint Bioscience AB's current Net Cash per Share is kr0.75. Based on the distribution chart, Sprint Bioscience AB ranks #319 out of 774 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sprint Bioscience AB has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #319 out of 774 companies for Net Cash per Share. This puts Sprint Bioscience AB in the upper half of its industry. The industry median Net Cash per Share is 4.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 4.92, based on 774 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Sprint Bioscience AB and its competitors. For the Biotechnology industry, the median Net Cash per Share is 4.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sprint Bioscience AB's current Net Cash per Share is kr0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Sprint Bioscience AB (OSTO:SPRINT) has a current Net Cash per Share of kr0.75. The current Net Cash per Share is kr0.75. Sprint Bioscience AB's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current Net Cash per Share is kr0.75 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
27GF Score
Get the complete analysis for OSTO:SPRINT
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPRINT has been successfully added to your 
